Receptor
From Proteopedia
(Difference between revisions)
| Line 7: | Line 7: | ||
These receptors are typically the targets of fast neurotransmitters such as acetylcholine (nicotinic) and GABA; activation of these receptors results in changes in ion movement across a membrane. | These receptors are typically the targets of fast neurotransmitters such as acetylcholine (nicotinic) and GABA; activation of these receptors results in changes in ion movement across a membrane. | ||
*[[Ionotropic receptors]] | *[[Ionotropic receptors]] | ||
| + | |||
| + | **[[5-hydroxytryptamine receptor#Structural highlights/Specific Function of 5-HT3]] | ||
==G protein-linked (metabotropic) receptors== | ==G protein-linked (metabotropic) receptors== | ||
This is the largest family of receptors and includes the receptors for several hormones and slow transmitters(dopamine, metabotropic glutamate). They are composed of seven transmembrane alpha helices. The loops connecting the alpha helices form extracellular and intracellular domains. The binding-site for larger peptide ligands is usually located in the extracellular domain whereas the binding site for smaller non-peptide ligands is often located between the seven alpha helices and one extracellular loop. These receptors are coupled to different intracellular effector systems via G proteins | This is the largest family of receptors and includes the receptors for several hormones and slow transmitters(dopamine, metabotropic glutamate). They are composed of seven transmembrane alpha helices. The loops connecting the alpha helices form extracellular and intracellular domains. The binding-site for larger peptide ligands is usually located in the extracellular domain whereas the binding site for smaller non-peptide ligands is often located between the seven alpha helices and one extracellular loop. These receptors are coupled to different intracellular effector systems via G proteins | ||
Revision as of 13:25, 8 April 2021
| |||||||||||
References
- ↑ Segaliny AI, Tellez-Gabriel M, Heymann MF, Heymann D. Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers. J Bone Oncol. 2015 Jan 23;4(1):1-12. doi: 10.1016/j.jbo.2015.01.001. eCollection , 2015 Mar. PMID:26579483 doi:http://dx.doi.org/10.1016/j.jbo.2015.01.001
